A small trial found 'a remarkable 100% of patients were still alive at 36 months' after receiving olaparib plus standard chemotherapy.
It's a"small but very powerful signal" of"what could be a potentially curative regimen that definitely does need to be confirmed in a larger study," Abraham added.trial, included 84 patients with T1-2 tumors of any hormone status. Just over 70% in both arms hadPast attempts at combining chemotherapy with PARP inhibitors have been hampered by excess bone marrow toxicity.
At a median follow-up of 40.7 months, 96% of patients in the combination arm demonstrated event-free survival, with one patient relapsing, vs 80% in the chemotherapy-alone group, with nine patients relapsing. The trial was stopped short at 50% enrollment after the data monitoring safety committee determined that olaparib add-on was unlikely to improve pathological complete response rates, the trial's primary endpoint."It didn't seem to matter whether you had a non-pathological complete response, you still survived 100%" with the combination, Abraham said, adding that this is not the first study to show a disconnect between response rates and survival.
First,"this is a very small population, so small differences in the biology of the tumor, the patients, and even stage that we can't assess in the neoadjuvant setting could make a difference that would affect event-free and overall survival," she said.
Lung Carcinoma Cancer Of The Lung Breast Cancer Malignant Breast Neoplasm Breast Carcinoma Ovarian Cancer Malignant Ovarian Neoplasm Ovary Cancer Chemotherapy Toxicology Toxicity Poisoning Toxins BRCA Breast Mammary Gland Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Biologic Therapy Biologics PARP Inhibitors PARP Inhibition
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Hundreds participate in ‘Walk to Cure Arthritis’ to help find a cureHundreds of people walked together Saturday to raise money to find a cure for arthritis.
Read more »
RNA's hidden potential: New study unveils its role in early life and future bioengineeringThe origin of life continues to remain a matter of debate. The ribonucleic acid (RNA) world hypothesis proposes that 'ribozymes' which store genetic information and possess catalytic functions may have supported the activities of early life forms.
Read more »
RNA's hidden potential: New study unveils its role in early life and future bioengineeringThe beginning of life on Earth and its evolution over billions of years continue to intrigue researchers worldwide.
Read more »
New Research Reveals Keto Diet’s Potential To Combat Early Alzheimer’sScience, Space and Technology News 2024
Read more »
Rangers' Bruce Bochy: Too early to panic over early-season bullpen issuesBoth David Robertson and José Leclerc were accountable postgame and took responsibility after Tuesday’s loss to Oakland.
Read more »
World’s 1st skin cancer vaccine enters final trial, offers personalized cureScientists are testing the world's first skin cancer vaccine, which has entered global trial. They aim for personalized treatment.
Read more »